Suzhou Zelgen Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-03-18
- Employees
- 867
- Market Cap
- -
- Website
- https://www.zelgen.com
Clinical Trials
77
Active:4
Completed:30
Trial Phases
4 Phases
Phase 1:42
Phase 2:19
Phase 3:12
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (77 trials with phase data)• Click on a phase to view related trials
Phase 1
42 (54.5%)Phase 2
19 (24.7%)Phase 3
12 (15.6%)Not Applicable
4 (5.2%)Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Not Applicable
Not yet recruiting
- Conditions
- Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 420
- Registration Number
- NCT07189455
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai Municipality, China
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: Gecacitinib
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 153
- Registration Number
- NCT07142837
- Locations
- 🇨🇳
Chinese PLA General Hosptial, Beijing, Beijing Municipality, China
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Biliary Tract Carcinoma
- Interventions
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT07099547
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Not Applicable
Not yet recruiting
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT07080216
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Small Cell Lung CancerNeuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 350
- Registration Number
- NCT07038096
- Prev
- 1
- 2
- 3
- 4
- 5
- 16
- Next
News
No news found